Pacritinib granted priority review by FDA for myelofibrosis

Priority review of this JAK2 and FLT3 inhibitor was accepted based on the data from the Phase 3 PERSIST-2 and PERSIST-1 clinical trials which found improvements in spleen volume and total symptom scores vs best available therapy (including ruxolitinib).

Source:

Biospace Inc.